About Maxygen
Maxygen is a publicly listed company based in Redwood City (United States) founded in 1997 by Willem Pim Stemmer. Protein drugs are developed for chemotherapy-induced neutropenia treatment. Maxygen offers products and services including EvoGenerative Methods and DNA Services. Its focus areas include Life Sciences, Genomics, Applied Genomics and Clinical Genomics. Its legal entity is MAXYGEN INC. Its competitors include Moderna, BridgeBio and BeiGene; 3 of its 3 listed competitors have raised funding.
Company details
Maxygen was founded in 1997 and is based in Redwood City, United States. Operations focus on biotechnology, with protein therapeutics provided for chemotherapy-induced neutropenia. A novel G-CSF is featured in clinical programs for this condition. Preclinical efforts include MAXY-4, a CTLA4-Ig developed for rheumatoid arthritis and other autoimmune diseases. Development occurs within the pharmaceutical sector targeting immune-related disorders.
- Headquarters Redwood City, United States
- Founders Willem Pim Stemmer
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Website maxygen.com
- Social LinkedIn
- Legal Name Maxygen Inc
- Annual Revenue$30.01 M (USD)5250as on Dec 31, 2012
- Net Profit$20.57 M (USD)-60as on Dec 31, 2012
- EBITDA$20.26 M (USD)273as on Dec 31, 2012
- Latest Funding Round$850.02K (USD), Grant
Sep 2008
- Investors
Products & Services of Maxygen
Maxygen offers a comprehensive portfolio of products and services, including EvoGenerative Methods and DNA Services.
Scalable library design for directed evolution in protein engineering.
Synthesis, assembly, and cloning technologies for biotechnology workflows.
Funding Insights of Maxygen
- Total Rounds 2
- Last Round Grant — $850,018
- First Round $3.43M
(Aug 2008)
- Investors Count 1
All 2 funding rounds of Maxygen with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2008 | $850,018 | Grant | – | – | |
| Aug 2008 | $3.43M | Grant | – | – |
1 investors in total: 1 institutional.
Investors in Maxygen
Maxygen has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Military Health.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Administers health care and support for military personnel and operations. | health.mil | Falls Church, United States |
Investor details for Maxygen
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Maxygen
2 people are tracked at Maxygen (2 in leadership).
| Name | Role | Group |
|---|---|---|
Willem Pim Stemmer | Founder | Leadership |
Michael Chambers | Interim CEO | Leadership |
Complete people profiles for Maxygen
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Maxygen
4 dated milestones of Maxygen across 11 years, from founding to its latest funding, stage changes and deals.
- Founded Maxygen is founded.
- IPO Lists on the stock exchange (IPO).
- Funding First funding round of $3.4M.
- Funding Latest funding round, Grant, of $850K.
Competitors of Maxygen
Maxygen has 3 listed competitors in our database, 3 of them funded. They include Moderna, BridgeBio and BeiGene.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| bridgebio.com | 2015 | Palo Alto, United States | $434.2M | Therapeutics for genetic diseases are developed through targeted interventions. | ||
| beigene.com | 2010 | Cambridge, United States | $172M | 1,090 | Targeted and immune-oncology drugs for cancer treatment are developed. |
Detailed competitors of Maxygen
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Maxygen
The website of Maxygen (maxygen.com) receives about 1.7K visits a month and ranks #10,660,575 among all websites worldwide, #7,954 in Biotechnology and Pharmaceuticals.
- Monthly visits1.7K
- Global rank#10,660,575
among all websites
- Category rank#7,954
Health · Biotechnology and Pharmaceuticals
- Bounce rate33%
- Pages per visit1.1
- DevicesDesktop 10% · Mobile 90%
Websites whose visitors overlap most with Maxygen. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| neurocrine.com | 100% | 39.1K | #927,855 | View details | |
| canfite.com | 100% | 4.5K | #4,278,330 | View details | |
| mannkindcorp.com | 100% | 23.2K | #1,557,758 | View details | |
gemacbio.com | gemacbio.com | 100% | – | ||
| xoma.com | 100% | 8K | #3,718,828 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 15 similar websites and full traffic analytics for Maxygen
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 15 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Maxygen (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Maxygen
Complete news archive for Maxygen
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Maxygen
Maxygen was founded in 1997 and raised its 1st funding round 11 years after it was founded.
Maxygen is headquartered in Redwood City, United States. It is registered at Redwood City, California, United States.
Annual revenue of Maxygen is $30.01M as on Dec 31, 2012.
Maxygen was founded in 1997 and is based in Redwood City, United States. Operations focus on biotechnology, with protein therapeutics provided for chemotherapy-induced neutropenia. A novel G-CSF is featured in clinical programs for this condition. Preclinical efforts include MAXY-4, a CTLA4-Ig developed for rheumatoid arthritis and other autoimmune diseases. Development occurs within the pharmaceutical sector targeting immune-related disorders.
Maxygen offers EvoGenerative Methods and DNA Services.
Maxygen has 1 investor. Key investors include Military Health.
Maxygen operates through Maxygen Inc.